Erasca is a clinical-stage precision oncology company driven by a bold mission—to erase cancer by shutting down one of cancer's most commonly mutated pathways.
Following #ENA2026 in Barcelona, Erasca will host a virtual investor event on November 20 at 8:00 a.m. ET, highlighting clinical momentum across our RAS-targeting franchise. To register and learn more, visit: https://t.co/YqB56co49c
Tomorrow is National Lung Cancer Screening Day. At Erasca, we support screening and early detection awareness as we advance ERAS-0015, an investigational therapy for RAS-mutant cancers. Learn more: https://t.co/ZOw7fj4YqI
#LCSDay2026#LCAM
Check out our Q3 2026 results and corporate updates, which highlight continued momentum across our pipeline as we advance toward our goal of developing treatments for #pancreatic and #lung cancers. More: https://t.co/V5JgL7T6I1
Erasca has won the @BioTech_Awards 2026 R&D Platform of the Year award! Thank you to our team, researchers, clinicians, patients and partners for helping advance our mission to erase cancer
Learn more about our work: https://t.co/WmFRvoNJMl
This November, Erasca’s management team will attend @GuggenheimSec, @Stifel, and @Jefferies#healthcare conferences to meet with investors and share progress in advancing therapies for RAS/MAPK-driven #cancers.
More here: https://t.co/qf7iqFIcG1
November is #LungCancerAwarenessMonth and #PancreaticCancerAwarenessMonth. We’re advancing new therapies for RAS/MAPK-driven cancers, including lung and pancreatic cancers, toward our mission of erasing cancer. Learn more: https://t.co/WmFRvoNJMl
Little Erascals, BIG Halloween spirit! 🎃 Our team and their families celebrated with costumes, trick-or-treating, snacks, and crafts. Here’s a peek at the fun! #TeamErasca#HappyHalloween
Thank you, @LustgartenFDN, for the Hope Through Science Award. We’re proud to support the shared mission of improving outcomes for patients with pancreatic cancer. #PancreaticCancer
RAS mutations drive ~30% of all cancers. Thank you, @stephaniesirota, for the opportunity to discuss Erasca’s journey and our commitment to advancing therapies for patients with RAS/MAPK-driven cancers. #ASCO2026
In our #ASCO2026 coffee break miniseries, RTW CBO @stephaniesirota chatted with Dr. Shannon Morris, Chief Medical Officer of @Erasca. Dr. Morris shared the story behind Erasca's name and what it took to pursue a corner of oncology that was historically considered undruggable. The mic drop moment is when Dr. Morris shares that RAS mutations drive 30% of all tumor types.
We’re proud to join Erasca in a strategic research and development collaboration to evaluate multiple agents from their pipeline targeting the RAS/MAPK pathway.
Learn more: https://t.co/H6aV57LauB @Erasca@SKopetz@DavidHongMD#EndCancer
Please join us for the @Erasca Virtual R&D Day on Lead Clinical Programs ERAS-007 & ERAS-601 in Advanced Solid Tumors featuring Dr. David Hong (MD Anderson Cancer Center). A live Q&A session will follow. Register Here: https://t.co/wcVbnN8jyD
Please join us on Tuesday, April 12th at 4:30 PM EDT for the @Erasca Investor Event featuring Scott Kopetz, M.D., Ph.D., (MD Anderson Cancer Center). A live Q&A session will follow. Register here: https://t.co/CsPgSdfHzA
A big, warm welcome to the @erascainc team! 👏👏👏
Erasca, Inc. joins us in Times Square to ring the @Nasdaq Opening Bell in honor of their IPO. 🎉 #EraseCancer
Welcome to the @Nasdaq family, @erascainc!
Erasca, Inc. is a clinical-stage precision oncology company driven by a bold mission: to erase cancer by shutting down one of cancer's most commonly mutated pathways. #EraseCancer
Now trading: $ERAS
.@erascainc is a clinical-stage precision oncology company driven by a bold mission—to erase cancer. We speak with CEO Jonathan E. Lim, M.D., about the company’s vision. https://t.co/MzN9mFg881